deCode Genetics, a leading biomarker discovery company under its CEO Kari Stefansson, seems to be stuck between the devil and the deep blue sea. Either it sells its profit-making drug development outlets in the US to safeguard its leading complex traits genetics operations, only to face a very ...
Please Login to read the full article.
